← Tuesday 27 Octobernote 5 of 13
Health researchTue 27 Oct 2026 · 5 of 13

Heme shown to inhibit clot‑dissolving enzyme, study finds

Unsupported claims · 4/5 supported1 cited · 1 min read

Medical Xpress reports that heme, a component of hemoglobin, can inhibit the enzyme plasmin that helps dissolve blood clots . Medical Xpress reports that the research was conducted by a team at the University of Koblenz led by Prof. Dr. Marie‑T. Hopp . Medical Xpress reports that the findings were published in the International Journal of Biological Macromolecules . Medical Xpress reports that the study provides a new molecular approach to understand the link between hemolysis and an increased risk of thrombosis .

Why it matters. Medical Xpress reports that the discovery could help develop strategies to mitigate thrombosis risk in conditions involving hemolysis .

Earlier on Health research

Mon 26 Oct 2026Bispecific ADC doubles PFS in HR+/HER2‑ breast cancerClinical Trials Arena reports that an $8.4bn bispecific ADC doubles progression‑free survival in HR+/HER2‑ breast cancer. Clinical Trials Arena reports that bispecific ADCs are viewed as the next generation of ADC development. Clinical Trials Arena reports that they continue to be the focus of high‑value dealmaking.Sun 25 Oct 2026Johns Hopkins APL's OsteoSEE Wins R&D 100 Award for Early Fracture DetectionMedical Xpress reports that researchers at Johns Hopkins Applied Physics Laboratory have developed Osteo Surface Echo Evaluation (OsteoSEE), a noninvasive ultrasound-based platform that uses surface acoustic waves to detect microstructural changes and early-stage tibial stress fractures. Medical Xpress reports that OsteoSEE avoids the use of ionizing radiation in fracture detection. Medical Xpress reports that the technology was named a 2026 R&D 100 Award winner. Medical Xpress reports that Anna Knight, the principal investigator, highlighted the platform's potential to support military readiness by enabling earlier detection of common overuse injuries in personnel.Sun 25 Oct 2026SGLT2 Inhibitors Show Mortality and Kidney Benefits but Higher Cardiac Risks in Adults 80+ with CKDMedical Xpress reports that the analysis used electronic health records of 10,076 adults aged 80 years or older with chronic kidney disease. Medical Xpress reports that initiating SGLT2 inhibitor therapy was linked to an 18% reduction in all‑cause mortality over a two‑year follow‑up. Medical Xpress reports that the same therapy was linked to a 22% reduction in major adverse kidney events over the same period. Medical Xpress reports that SGLT2 inhibitors showed no significant effect on major adverse cardiovascular events overall, but were associated with higher risks of specific cardiac events such as heart attacks and acute heart failure. Medical Xpress reports that SGLT2 inhibitors were also associated with a higher risk of acute kidney injury, and the findings will be presented at ASN Kidney Week 2026 on October 22–25.
Next · Formula 1Russell calls his US Grand Prix pace 'rubbish' as Antonelli dominates →